Table 2.
History, Severity of Injury and Treatment Stratified by Levetiracetam Prophylaxis
| Variable | Prophylaxis | No Prophylaxis | P |
|---|---|---|---|
|
| |||
| N | 38 | 104 | |
|
| |||
| History of Intracerebral Hemorrhage | 2 (5) | 3 (3) | 0.6 |
|
| |||
| History of Diabetes | 8 (21) | 18 (17) | 0.6 |
|
| |||
| History of Ischemic Stroke | 6 (16) | 15 (14) | 0.8 |
|
| |||
| History of Coronary Artery Disease | 3 (8) | 7 (7) | 0.8 |
|
| |||
| History of Atrial Fibrillation | 4 (10) | 5 (5) | 0.2 |
|
| |||
| History of Hypertension | 30 (79) | 81 (78) | 0.9 |
|
| |||
| History of Dementia | 0 | 2 (2) | 0.4 |
|
| |||
| Lobar Hematoma | 27 (71) | 19 (18) | <0.001 |
|
| |||
| APACHE Predicted Length of Stay, days | 4.9 [4.0 – 6.7] | 4.7 [4.3 – 5.9] | 0.5 |
|
| |||
| APACHE Acute Physiology Score Points | 27 [19.5 – 56] | 25 [18.5 – 36.5] | 0.4 |
|
| |||
| APACHE Predicted Mortality (%) | 13 [4.2 – 25.6] | 10 [4.6 – 20.1] | 0.6 |
|
| |||
| Lorazepam, 0 mg | 32 (84) | 80 (77) | 0.2 |
| 1 mg | 3 (8) | 15 (14) | |
| 2 mg | 1 (3) | 8 (8) | |
| 4 – 8 mg | 2 (5) | 1 (1) | |
|
| |||
| Midazolam, 0 mg | 21 (55) | 78 (75) | 0.2 |
| 0.5 - 1 mg | 6 (16) | 12 (15) | |
| 1.5 - 2 mg | 7 (18) | 9 (12) | |
| 2.5 - 5.5 mg | 4 (11) | 5 (6) | |
|
| |||
| Ventilator Free Days in first 14 days | 14 [7 – 14] | 14 [12 – 14] | 0.2 |
|
| |||
| Days with Fever at least 100.4 in first 14 days | 0 [0 – 2] | 0 [0 – 0] | 0.3 |
APACHE, Acute Physiology and Chronic Health Evaluation IV.
Data are median [Q1 – Q3] or N(%) as appropriate